Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0W9ZF
|
||||
| Former ID |
DAP001420
|
||||
| Drug Name |
Quinagolide
|
||||
| Synonyms |
Quinagolida; Quinagolidum; CV 205-502; CV205-502; Norprolac (TN); Quinagolida [INN-Spanish]; Quinagolide [BAN:INN]; Quinagolidum [INN-Latin]; CV-205-502; Quinagolide (INN/BAN); Quinagolide, (3alpha,4aalpha,10abeta)-(+-)-isomer; N,N-diethyl-N'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzo(g)quinolinyl)sulfamide, (3alpha,4aalpha,10abeta)-(+-)-isomer; (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamide; (3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline; 3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hyperprolactinemia [ICD9: 253.1; ICD10:E22.1] | Approved | [1] | ||
| Therapeutic Class |
Fertility Agents
|
||||
| Company |
Ferring Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H33N3O3S
|
||||
| Canonical SMILES |
CCCN1CC(CC2C1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC
|
||||
| InChI |
1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3
|
||||
| InChIKey |
GDFGTRDCCWFXTG-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 97805-50-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
G02CB04
|
||||
| SuperDrug CAS ID |
cas=087056788
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [2] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| REF 2 | Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol. 2002 Jun;136(4):620-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.